
Pharmaceutical company Novo Nordisk is reducing the direct-to-consumer monthly cost of its popular weight loss and diabetes drugs, Wegovy and Ozempic, from $499 to $349. This significant price cut is a departure from their original $1000 per month price tag. Additionally, an introductory offer allows patients paying cash to get the first two months for $199.